Gene regulation of retinal cell differentiation

视网膜细胞分化的基因调控

基本信息

  • 批准号:
    8656122
  • 负责人:
  • 金额:
    $ 40.92万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-05-01 至 2018-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Gene regulation of retinal cell differentiation in development is crucial for the generation of mature and functional retinal neurons that form the cellular basis of visual function. Dysregulation in retinal development causes developmental abnormalities of eye and impairs visual function. Stem cell-based regenerative medicine and cell replacement therapy require a better understanding of key developmental regulators and signal pathways in retinal cell differentiation. Our long-term goal of this proposal is to elucidat those molecular mechanisms that control the maintenance of multipotential retinal progenitor cells (RPCs) and their subsequent photoreceptor cell commitment. We predict that RPC-multipotency factors (providing differentiation potentials) and lineage-specific signals act in concert to initiate the expression of decision-making gene(s) that steer(s) a subset of RPCs towards the photoreceptor lineage. However, not much is known about the molecular events in the regulation of RPC multipotency and the initiation of photoreceptor cell differentiation. Homeodomain transcription factors Six3 and Six6 are structurally similar and largely co-expressed in multipotent RPCs in mouse. Our current preliminary studies have identified severe RPC defects in Six3; Six6 compound null retinas; these RPC defects are not evident in either Six3 or Six6 single null retinas. In photoreceptor cell differentiation, homeodomain transcription factor Otx2 is the earliest marker and the essential upstream regulator in a gene network that direct photoreceptor precursors to either rods or cones. Thus, Otx2 is a decision-making gene whose expression marks cell commitment, and dissection of the regulatory components for its neuroretinal expression help unravel as yet unknown molecular mechanisms that promote RPCs to differentiate into photoreceptor precursors. Now we have identified a novel, highly conserved enhancer that recapitulates the initial Otx2 retinal expression. In this proposal we aim 1) to elucidate the regulatory pathways under the control of Six3/Six6 joint functions in retinal cell differentiation and 2) to determine the molecular mechanisms that control Otx2 retinal expression through this Otx2 retinal enhancer. The outcomes of these studies will provide insights into the molecular mechanisms controlling the maintenance of multipotential retinal progenitor cells and photoreceptor cell differentiation, and thus facilitate the design of novel strategies for the generation of specific retinal cells, e.g., photoreceptor cells, from the culturs of human embryonic stem cells or induced pluripotent stem cells in the endeavor of modeling and treatment of human retinal diseases.
描述(由申请人提供):发育过程中视网膜细胞分化的基因调控对于形成成熟和功能性视网膜神经元至关重要,视网膜神经元构成视觉功能的细胞基础。视网膜发育失调导致眼发育异常,损害视觉功能。基于干细胞的再生医学和细胞替代疗法需要更好地理解视网膜细胞分化的关键发育调节因子和信号通路。我们的长期目标是阐明那些控制维持多潜能视网膜祖细胞(rpc)及其随后的感光细胞承诺的分子机制。我们预测,rpc -多能因子(提供分化潜能)和谱系特异性信号协同作用,启动决策基因的表达,引导rpc子集向光感受器谱系发展。然而,关于RPC多能性调控和光感受器细胞分化起始的分子事件知之甚少。同源结构域转录因子Six3和Six6结构相似,在小鼠多能性rpc中大量共表达。我们目前的初步研究已经确定了Six3的严重RPC缺陷;6个复合无视网膜;这些RPC缺陷在Six3或Six6单个空视网膜中都不明显。在光感受器细胞分化过程中,同源结构域转录因子Otx2是基因网络中最早的标记物,也是引导光感受器前体分化为视杆细胞或视锥细胞的重要上游调控因子。因此,Otx2是一个决策基因,其表达标志着细胞承诺,而对其神经视网膜表达调控成分的解剖有助于揭示促进RPCs分化为光受体前体的未知分子机制。现在我们已经确定了一种新的,高度保守的增强子,它概括了最初的Otx2视网膜表达。在本研究中,我们的目标是:1)阐明Six3/Six6联合功能在视网膜细胞分化中的调控途径;2)确定通过这种Otx2视网膜增强剂控制Otx2视网膜表达的分子机制。这些研究的结果将提供对控制多潜能视网膜祖细胞和光感受器细胞分化维持的分子机制的见解,从而促进从人类胚胎干细胞或诱导多能干细胞培养中产生特定视网膜细胞(如光感受器细胞)的新策略的设计,以努力模拟和治疗人类视网膜疾病。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

WEI LIU其他文献

WEI LIU的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('WEI LIU', 18)}}的其他基金

Gene regulation of retinal cell differentiation
视网膜细胞分化的基因调控
  • 批准号:
    8505081
  • 财政年份:
    2013
  • 资助金额:
    $ 40.92万
  • 项目类别:
Gene regulation of retinal cell differentiation
视网膜细胞分化的基因调控
  • 批准号:
    10478103
  • 财政年份:
    2013
  • 资助金额:
    $ 40.92万
  • 项目类别:
Gene regulation of retinal cell differentiation
视网膜细胞分化的基因调控
  • 批准号:
    9887357
  • 财政年份:
    2013
  • 资助金额:
    $ 40.92万
  • 项目类别:
Gene regulation of retinal cell differentiation
视网膜细胞分化的基因调控
  • 批准号:
    10248296
  • 财政年份:
    2013
  • 资助金额:
    $ 40.92万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 40.92万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 40.92万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 40.92万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 40.92万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 40.92万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 40.92万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 40.92万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 40.92万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 40.92万
  • 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
  • 批准号:
    10534864
  • 财政年份:
    2023
  • 资助金额:
    $ 40.92万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了